| Latest Protalix Biotherapeutics News Headlines | | Date | Time | Source | | | 02/12/2008 | 9:00AM | PRNUS | Protalix BioTherapeutics Appoints Professor Roger D. Kornberg to Board of Directors
CARMIEL, Israel, Feb. 12 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (AMEX:PLX), announced today that Professor Roger D. Kornberg, renowned Biochemist and laureate of the Nobel Prize in Chemistry, has been appointed to the Company's board of directors.
Professor Kornberg is a member of the U.S. National... More...>> |
| 01/22/2008 | 8:30AM | PRNUS | Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Anima
CARMIEL, Israel, Jan. 22 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (AMEX:PLX), today announced that it has achieved proof of concept results in an animal study conducted as part of its Acetylcholinesterase (AChE) Program. The Acetylcholinesterase (AChE) Program is being conducted under the agreement... More...>> |
| 01/14/2008 | 8:30AM | PRNUS | Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
CARMIEL, Israel, Jan. 14 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (AMEX:PLX), announced today that it has signed a lease agreement for the expansion of its manufacturing and research facility. The expanded space, located in the Company's facility in Carmiel, Israel, will provide the Company with approximately... More...>> |
| 12/05/2007 | 10:56AM | PRNUS | Protalix BioTherapeutics Announces Resignation of Board Members
CARMIEL, Israel, Dec. 5 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (AMEX:PLX), announced today that two of its directors, Phillip Frost, M.D. and Jane H. Hsiao, Ph.D., have resigned from the Company's Board of Directors, effective immediately. Both resigned for personal reasons. Dr. Hsiao was a member... More...>> |
| 12/03/2007 | 8:46AM | PRNUS | Protalix BioTherapeutics' prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific
CARMIEL, Israel, Dec. 3 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (AMEX:PLX), noted today that prGCD, the Company's proprietary recombinant form of Glucocerebrosidase (GCD), which is used as an enzyme replacement therapy for Gaucher disease, was named one of the Five Most Promising Drugs Entering Phase... More...>> |
| 11/29/2007 | 8:46AM | PRNUS | Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
CARMIEL, Israel, Nov. 29 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (AMEX:PLX), today announced that its board of directors has set the close of business on December 24, 2007, as the record date for shareholders entitled to receive notice of, and to vote at, the Company's 2007 Annual Meeting of Shareholders... More...>> |
| 11/02/2007 | 4:54PM | PRNUS | Protalix BioTherapeutics to Present at CIBC World Markets 18th Annual Healthcare Conference
CARMIEL, Israel, Nov. 2 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (AMEX:PLX), today announced that Dr. David Aviezer, Ph.D., its President and Chief Executive Officer, will present at the CIBC World Markets 18th Annual Healthcare Conference. Dr. Aviezer's presentation will take place at 3:00 p.m. EST... More...>> |
| 10/24/2007 | 6:25PM | PRNUS | Protalix BioTherapeutics Announces Pricing of Public Offering of Common Stock
CARMIEL, Israel, Oct. 24 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (AMEX:PLX), announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share. The Company has granted a 30-day option to the underwriters to purchase... More...>> |
| 10/07/2007 | 7:13PM | PRNUS | Protalix BioTherapeutics Announces Public Offering of Common Stock
CARMIEL, Israel, Oct. 7 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (AMEX:PLX), today announced that it has commenced a proposed underwritten public offering of its common stock pursuant to a preliminary prospectus supplement to its effective shelf registration statement. The company is proposing to sell... More...>> |
| 09/28/2007 | 8:30AM | PRNUS | Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
CARMIEL, Israel, Sept. 28 /PRNewswire-FirstCall/ -- The Russell Investment Group has advised Protalix Biotherapeutics (AMEX:PLX) that there will be a float weight adjustment effective after the close of trading on September 28, 2007 in the following indexes: Russell 2000, Russell 2000 Growth, Russell 2500, Russell 2500... More...>> |
| 09/19/2007 | 9:39AM | PRNUS | Protalix BioTherapeutics to Present at UBS Global Life Sciences Conference
CARMIEL, Israel, Sept. 19 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (AMEX:PLX), today announced that Dr. David Aviezer, its President and Chief Executive Officer, will present at the UBS Global Life Sciences Conference at the Grand Hyatt New York on Monday, September 24, 2007, at 9:30 a.m. EDT.
The Company's... More...>> |
| 08/27/2007 | 9:16AM | PRNUS | Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
First patient treated in trial of prGCD treatment of Gaucher Disease
CARMIEL, Israel, Aug. 27 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (AMEX:PLX), today announced that it has treated the first patient in its phase III clinical trial of the Company's lead product candidate, prGCD, a proprietary plant... More...>> |
| 08/08/2007 | 9:30AM | PRNUS | Protalix BioTherapeutics Signs Agreement to License Acetylcholinestrase Development Technology
Protalix BioTherapeutics to Explore Biodefense and Civilian Applications with Researchers from Hebrew University of Jerusalem
CARMIEL, Israel, Aug. 8 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (AMEX:PLX), today announced it has signed an agreement with the Yissum Research and Development Company, the technology... More...>> |
| 08/06/2007 | 9:06AM | PRNUS | Protalix BioTherapeutics Appoints Prof. Aaron Ciechanover, a Laureate of the Nobel Prize in Chemistry, to its Scientific Advisor
CARMIEL, Israel, Aug. 6 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (AMEX:PLX), today announced the appointment of Professor Aaron Ciechanover, a laureate of the Nobel Prize in Chemistry, to its Scientific Advisory Board.
Born in Haifa, Israel, Professor Ciechanover received his Master of Science in 1971... More...>> |
| 07/13/2007 | 3:23PM | PRNUS | Protalix BioTherapeutics, Inc. Receives Special Protocol Assessment Approval from FDA for its Phase III Clinical Study of prGCD
Company Expects to Begin Enrolling Gaucher Disease Patients for Phase III Clinical Trials of prGCD in Third Quarter of 2007
CARMIEL, Israel, July 13 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (AMEX:PLX) today announced that it has reached an agreement with the United States Food and Drug Administration... More...>> |
| 06/26/2007 | 11:24AM | PRNUS | Protalix BioTherapeutics Added to Russell 3000(R) Index
CARMIEL, Israel, June 26 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (AMEX:PLX) today announced that its shares have been added to the broad market Russell 3000(R) Index. The Russell Investment Group reconstituted its comprehensive set of U.S. and global equity indexes following the close of the U.S. markets... More...>> |
| 06/20/2007 | 9:17AM | PRNUS | Protalix BioTherapeutics Plans to Offer Common Stock to the Public
CARMIEL, Israel, June 20 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (AMEX:PLX), announced today that its Board of Directors has authorized it to prepare and file with the Securities and Exchange Commission a registration statement pursuant to which the Company and certain selling shareholders may offer... More...>> |
| 06/04/2007 | 9:34AM | PRNUS | Protalix BioTherapeutics Appoints Dr. Ernest Beutler to its Scientific Advisory Board
CARMIEL, Israel, June 4 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (AMEX:PLX), today announced the appointment of Professor Ernest Beutler, M.D., to its Scientific Advisory Board.
Professor Beutler serves as Professor and Chairman of the Department of Molecular and Experimental Medicine at The Scripps... More...>> |
| 05/03/2007 | 4:44PM | PRNUS | Protalix BioTherapeutics to Present at the BIO International Convention on May 7, 2007
CARMIEL, Israel, May 3 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics (AMEX:PLX) today announced that Dr. David Aviezer, President and Chief Executive Officer, will present at the Biotechnology Industry Organization's (BIO), 2007 International Convention on Monday, May 7, 2007 at 10:20 a.m. EDT, at the Boston Convention... More...>> |
| 04/18/2007 | 7:00AM | PRNUS | Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
Phase III clinical trial may commence shortly
CARMIEL, Israel, April 18 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (AMEX:PLX) today announced that it has received written notice from the United States Food and Drug Administration (FDA) that it may initiate a Phase III clinical trial in the United States... More...>> |
|